MedTrace Logo

Women's Angiographic Vitamin and Estrogen Trial (WAVE)

NCT00000555 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2016-07-12

No results posted yet for this study

Summary

To assess whether hormonal replacement therapy and/or antioxidant treatment would stabilize or inhibit progression, and induce regression of coronary plaques. The mechanisms by which these treatments modified atherosclerosis in women were also explored.

Conditions

  • Cardiovascular Diseases
  • Coronary Arteriosclerosis
  • Coronary Disease
  • Heart Diseases
  • Myocardial Ischemia
  • Postmenopause

Interventions

DRUG

estrogen replacement therapy

DRUG

estrogens, conjugated

DRUG

progesterone

DRUG

hormone replacement therapy

DRUG

supplementation, food

DRUG

ascorbic acid

DRUG

vitamin e

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • Joel Verter · George Washington University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
38 Years
Max Age
86 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-08-31
Completion
2003-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000555 on ClinicalTrials.gov